Freedom Investment Management Inc. Purchases 14,496 Shares of Hologic, Inc. $HOLX

Key Points

• Freedom Investment Management Inc. increased its stake in Hologic, Inc. by 370.8%, purchasing an additional 14,496 shares, bringing its total holdings to 18,405 shares valued at approximately $1.137 million.
• Several institutional investors raised their stakes in Hologic, with 94.73% of the company's stock now owned by institutional investors.
• Analysts have mixed views on Hologic, with the stock receiving a range of ratings including one Strong Buy, eight Buy, and eight Hold ratings, and an average price target set at $78.00.

Freedom Investment Management Inc. increased its position in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 370.8% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 18,405 shares of the medical equipment provider's stock after purchasing an additional 14,496 shares during the quarter. Freedom Investment Management Inc.'s holdings in Hologic were worth $1,137,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently bought and sold shares of HOLX. Dark Forest Capital Management LP grew its stake in Hologic by 7.9% in the fourth quarter. Dark Forest Capital Management LP now owns 3,053 shares of the medical equipment provider's stock worth $220,000 after purchasing an additional 223 shares in the last quarter. Voya Investment Management LLC grew its stake in Hologic by 9.9% in the fourth quarter. Voya Investment Management LLC now owns 138,891 shares of the medical equipment provider's stock worth $10,013,000 after purchasing an additional 12,488 shares in the last quarter. Kovitz Investment Group Partners LLC bought a new position in Hologic in the fourth quarter worth approximately $264,000. Nebula Research & Development LLC grew its stake in Hologic by 140.9% in the fourth quarter. Nebula Research & Development LLC now owns 16,129 shares of the medical equipment provider's stock worth $1,163,000 after purchasing an additional 9,434 shares in the last quarter. Finally, Coldstream Capital Management Inc. grew its stake in Hologic by 10.0% in the fourth quarter. Coldstream Capital Management Inc. now owns 10,354 shares of the medical equipment provider's stock worth $746,000 after purchasing an additional 944 shares in the last quarter. Institutional investors own 94.73% of the company's stock.

Analyst Ratings Changes

HOLX has been the topic of several research analyst reports. Stephens dropped their price objective on Hologic from $77.00 to $70.00 and set an "overweight" rating on the stock in a research note on Tuesday, May 13th. Wall Street Zen raised Hologic from a "hold" rating to a "buy" rating in a research report on Friday. Raymond James Financial reaffirmed an "outperform" rating and set a $71.00 target price (down previously from $90.00) on shares of Hologic in a research report on Friday, May 2nd. Citigroup raised Hologic from a "neutral" rating to a "buy" rating and increased their target price for the company from $60.00 to $80.00 in a research report on Wednesday, July 9th. Finally, Royal Bank Of Canada raised Hologic from a "sector perform" rating to an "outperform" rating and increased their target price for the company from $72.00 to $87.00 in a research report on Wednesday, August 6th. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and eight have issued a Hold rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $78.00.

Hologic Stock Performance

Shares of HOLX stock opened at $68.26 on Monday. The firm has a market capitalization of $15.18 billion, a price-to-earnings ratio of 28.32, a price-to-earnings-growth ratio of 2.48 and a beta of 0.49. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.55 and a quick ratio of 2.81. The business has a fifty day moving average of $65.90 and a 200 day moving average of $62.40. Hologic, Inc. has a 1 year low of $51.90 and a 1 year high of $84.39.

Hologic (NASDAQ:HOLX - Get Free Report) last issued its earnings results on Wednesday, July 30th. The medical equipment provider reported $1.08 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.05 by $0.03. The company had revenue of $1.02 billion during the quarter, compared to analyst estimates of $1.01 billion. Hologic had a return on equity of 19.69% and a net margin of 13.79%.The firm's quarterly revenue was up 1.2% on a year-over-year basis. During the same quarter last year, the business posted $1.06 EPS. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. As a group, research analysts expect that Hologic, Inc. will post 4.28 earnings per share for the current year.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.

Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.